EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors

Ejemplares similares

• EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
  por: Vasconcelos, Pedro E.N.S., et al.
  Publicado: (2020)
• EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
  por: Kobayashi, Ikei S., et al.
  Publicado: (2021)
• Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
  por: Yang, Lu, et al.
  Publicado: (2020)
• Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
  por: Dufort, Sandrine, et al.
  Publicado: (2011)
• Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases
  por: Zhi, Xiaoyu, et al.
  Publicado: (2021)